Effect of shenqi fuzheng injection for hemopoietic and immune function reconstruction in patients with hematologic malignancies undergoing chemotherapy.
- Author:
Xiao-yu ZHU
1
;
Xiang-zhong ZHANG
;
Xue-yun ZHONG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antineoplastic Agents; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Drugs, Chinese Herbal; therapeutic use; Female; Hematologic Neoplasms; drug therapy; immunology; Hemoglobins; analysis; Humans; Injections; Leukocyte Count; Male; Middle Aged; Phytotherapy; Remission Induction; T-Lymphocyte Subsets; immunology; Treatment Outcome; Young Adult
- From: Chinese Journal of Integrated Traditional and Western Medicine 2010;30(2):205-207
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of Shenqi Fuzheng Injection (SFI) for hemopoietic and immune function reconstruction in patients with hematologic malignancies (HM) after chemotherapy.
METHODSEighty HM patients at remission inducing stage of initial treatment were randomly assigned to two groups, the treatment group treated with SFI (250 mL daily) plus chemotherapy and the control group only treated with chemotherapy for 14 days, with same supportive treatments administered to both. Levels of blood routine test, T lymphocyte subsets (CD3+, CD4+, CD4+ /CD8+) and B lymphocyte subsets CD3- CD19+ were determined before and after treatment, and the remission rate was assessed after treatment.
RESULTSThe remission rates in the two groups showed no significant difference [90% (36/40) vs 82.5% (33/40), P > 0.05] statistically. Levels of peripheral leucocyte count and hemoglobin as well as levels of CD3+, CD4+, CD4+ /CD8+; were significantly higher in the treatment group than in the control group (P < 0.05), but no significant difference was shown between groups in CD3- CD19+ level.
CONCLUSIONSFI can lighten the inhibition of chemotherapy on hemopoietic function of bone marrow, and promote its recovery, enhance the immune function, and improve the quality of life in patients with HM undergoing chemotherapy.
